X

Trial Profile

RENal Hemodialysis Patients ALlocated Apixaban Versus Warfarin in Atrial Fibrillation (RENAL-AF) Randomized Clinical Trial

Status: Discontinued

Phase of Trial: Phase IV

Latest Information Update: 09 Nov 2022

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Apixaban (Primary) ; Warfarin (Primary)
Indications Stroke; Thromboembolism
Focus Adverse reactions
Acronyms RENAL-AF

Most Recent Events

06 Nov 2022 Status changed to discontinued.
06 Nov 2022 Results assessing safety or efficacy of apixaban for stroke prevention in patients with end-stage kidney disease (ESKD) on hemodialysis and with atrial fibrillation, published in the Circulation.
01 Sep 2020 Results of pharmacokinetic parameter (n=63) presented at the ESC Congress 2020 - Annual Congress of the European Society of Cardiology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com